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ABSTRACT
Anaplastic (ATC) and certain follicular thyroid-carcinomas (FTCs) are 
radioresistant. The Phosphatidylinositide 3-kinase (PI3K) pathway is commonly 
hyperactivated in thyroid-carcinomas. PI3K can modify the PI3K-related kinases 
(PIKKs) in response to radiation: How PIKKs interact with PI3K and contribute to 
radioresistance in thyroid-carcinomas is unknown. Further uncertainties exist in how 
these interactions function under the radioresistant hypoxic microenvironment. 
Under normoxia/anoxia, ATC (8505c) and FTC (FTC-133) cells were irradiated, with 
PI3K-inhibition (via GDC-0941 and PTEN-reconstitution into PTEN-null FTC-133s) and 
effects on PIKK-activation, DNA-damage, clonogenic-survival and cell cycle, assessed. 
FTC-xenografts were treated with 5 × 2 Gy, ± 50 mg/kg GDC-0941 (twice-daily; orally) 
for 14 days and PIKK-activation and tumour-growth assessed. PIKK-expression was 
additionally assessed in 12 human papillary thyroid-carcinomas, 13 FTCs and 12 ATCs. 
GDC-0941 inhibited radiation-induced activation of Ataxia-telangiectasia mutated 
(ATM), ATM-and Rad3-related (ATR) and DNA-dependent protein kinase catalytic 
subunit (DNA-PKcs). Inhibition of ATM and DNA-PKcs was PI3K-dependent, since 
activation was reduced in PTEN-reconstituted FTC-133s. Inhibition of PIKK-activation 
was greater under anoxia: Consequently, whilst DNA-damage was increased and 
prolonged under both normoxia and anoxia, PI3K-inhibition only reduced clonogenic-
survival under anoxia. GDC-0941 abrogated radiation-induced cell cycle arrest, an effect 
most likely linked to the marked inhibition of ATR-activation. Importantly, GDC-0941 
inhibited radiation-induced PIKK-activation in FTC-xenografts leading to a significant 
increase in time taken for tumours to triple in size: 26.5 ± 5 days (radiation-alone) 
versus 31.5 ± 5 days (dual-treatment). PIKKs were highly expressed across human 
thyroid-carcinoma classifications, with ATM scoring consistently lower. Interestingly, 
some loss of ATM and DNA-PKcs was observed. These data provide new insight into 
the mechanisms of hypoxia-associated radioresistance in thyroid-carcinoma.
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INTRODUCTION
Anaplastic thyroid carcinomas (ATC) and subsets 
of follicular thyroid carcinomas (FTC) are aggressive, 
metastatic and resistant to conventional radiotherapy. 
Molecular-based targeting of dysregulated signalling 
cascades including the phosphatidylinositol 3-kinase 
(PI3K), mitogen-activated protein kinase (MAPK) and 
related proteins (BRAF, RAS and RET) as single or multi-
modal chemotherapeutics look promising for the treatment 
of differentiated thyroid cancer. However, available 
clinical results highlight a need for more efficacious 
combined chemo/radiotherapy treatment modalities for 
the aggressive, therapy resistant subsets [1–3]. 
DNA damage induced for example, by radiotherapy 
activates the DNA damage response (DDR) that involve 
three major groups of proteins that act in concert to 
translate the DNA damage signal into a functional 
response principally involving cell cycle arrest and DNA 
repair. These proteins sense the DNA lesions and recruit 
transducer proteins that relay and amplify the damage 
signal to effector proteins. 
A class of proteins rapidly activated in response 
to DNA damage is the PI3K-related kinases (PIKKs): 
Members include Ataxia-telangiectasia mutated (ATM), 
ATM- and Rad3-related (ATR) and DNA-dependent 
protein kinase catalytic subunit (DNA-PKcs), which 
function principally as transducer proteins. ATM and 
DNA-PKcs respond to double-stranded DNA breaks, 
whilst ATR is activated by single-stranded DNA breaks 
and stalled replication forks. The PIKKs phosphorylate 
many proteins that act to maintain genomic integrity by 
promoting DNA repair, controlling cell cycle progression, 
transcription and apoptosis (reviewed in [4, 5]). DNA 
repair may enable tumour cells to survive breaks induced 
by DNA-damaging treatments [6] such as radiotherapy 
leading to radioresistance. 
The DNA repair capacity of a tumour cell is 
highly influenced by PIKK activity and their interactions 
with additional oncogenic signalling cascades. The 
phosphatidylinositide 3-kinase (PI3K) pathway is 
commonly hyperactivated in follicular (FTC) and 
anaplastic thyroid carcinomas (ATC) and contributes to 
aggressive transition and radioresistance [1, 7]. However, 
the mechanism of PI3K-mediated radioresistance in 
thyroid carcinoma is not well understood. In selective 
tumour types that exhibit hyperactive PI3K signalling, 
the PIKK proteins are modulated by PI3K in response 
to DNA damage. The relationship between PI3K and 
PIKK activation in irradiated cancer cells is complex 
and differs between tumour types. Modulation of PIKK 
activity by PI3K is also specific to certain PIKKs. For 
example, PI3K contributes to ATM activation induced by 
ionizing radiation in a T cell leukemia cell line, whilst in 
a study involving lung epithelial carcinoma cells PI3K 
modulated radiation-induced DNA-PKcs activity and had 
no effect on ATM [8, 9]. Further complexities exist in 
that other PI3K-pathway members can be independently 
activated by PIKKs and vice versa. For example, ATM is 
required for phosphorylation and full activation of AKT 
in response to radiation-induced damage, validated in a 
range of cell lines including fibroblasts derived from ATM 
knock-out mice and patients with ataxia telangiectasia. 
Additionally AKT has been reported to act both upstream 
and downstream of DNA-PKcs to promote tumour cell 
survival post-radiotherapy [10–13]. 
Additional uncertainties exist on the relative 
contribution of these interactions under hypoxia, a tumour 
condition that contributes significantly to radioresistance. 
Hypoxic cells are inherently radioresistant as oxygen is 
required for the generation of DNA damage. The interplay 
between the PI3K and the Hypoxia-inducible factor (HIF) 
pathways contributes to tumour progression and metastasis 
in thyroid carcinoma, and radiotherapy has been shown to 
enhance metastastic characteristics in models of FTC and 
ATC via enhanced PI3K/Hypoxia-inducible factor (HIF) 
signalling [14]. Both pathways contribute significantly to 
radioresistance of many cancers. 
How the apparent activation of PIKKs contributes 
to radioresistance in thyroid carcinoma has not been 
evaluated and the relative contribution by the PI3K 
pathway is unknown. Our main objectives were to a) 
assess the relationship between PI3K and the PIKKs 
in irradiated thyroid cancer cells b) determine if PI3K 
inhibition altered the observed radioresistant phenotypes in 
cells and xenografts and c) establish a clinical relevance in 
primary human tumours. 
To address this, we used cell lines representative of 
ATC (8505c) and FTC (FTC-133) that have previously 
been linked to PI3K activation and aggressive transition 
in response to radiotherapy in preclinical models [14]. 
Furthermore, the FTC-133 cell line was used since it 
originates from an FTC lymph node metastasis and responds 
poorly to radioiodine [15]. Clinically, subsets of FTC that 
are phenotypically similar to this cell line may be treated 
with external beam radiotherapy, similarly to ATC [1, 16]
We first treated cells with GDC-0941 to 
pharmacologically inhibit PI3K and determined effects 
on radiation-induced PIKK activation. Further we used a 
pair of FTC-133 cell lines: one containing a control vector 
and the other stably transfected with phosphatase and 
tensin homolog (PTEN), to genetically inhibit the PI3K 
pathway, since the parental FTC-133 cell line lacks PTEN. 
In addition to normoxia, studies were performed under 
anoxia to mimic a condition of high radioresistance and 
determine any differences in PI3K/PIKK activity between 
different oxygen tensions. We next assessed if GDC-0941 
radiosensitised FTC xenografts and related this to effects 
on PIKK activation. To ascertain a potential clinical 
relevance of PIKKs, we assessed total PIKK expression 
in primary thyroid carcinoma samples representative of 
PTC, FTC and ATC and in normal thyroid tissue.
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RESULTS
Radiation-induced PIKK activation is 
differentially modified by pharmacological 
(GDC-0941) and genetic inhibition of PI3K in 
normoxia and anoxia 
To evaluate whether pharmacological targeting of 
PI3K influenced PIKK activation we assessed the effect 
of GDC-0941 on radiation-induced PIKK activation in 
normoxia and anoxia via analysis of phospho-(p)PIKK 
expression. We used two thyroid models, the follicular 
cell line FTC-133 and the anaplastic model 8505c. Under 
normoxic conditions, pATM was relatively unchanged 
by increasing doses of GDC-0941 in both FTC-133 and 
8505c cells (Figure 1). Under anoxic conditions ATM 
activation was clearly diminished by GDC-0941 treatment 
in FTC-133 and 8505c cells. Although the effect in 8505c 
cells was less marked. pDNA-PKcs was inhibited to a 
much greater extent by GDC-0941 under anoxia in both 
cell lines, with 1 µM sufficient to ablate activation. Similar 
effects in normoxia required doses of > 50 µM or 100 µM 
in FTC-133 and 8505c cells respectively. In contrast 
pATR levels after radiation treatment were significantly 
compromised by 1 µM GDC-0941 in both cell lines under 
both oxygen conditions (Figure 1). Previous work has 
demonstrated that GDC-0941 can directly inhibit DNA-
PKcs [17]. Consistently pDNA-PKcs was reduced by 
GDC-0941 alone in FTC-133 cells (data not shown). In 
unirradiated 8505c cells, pDNA-PKcs was undetectable. 
pAKT was used as a downstream biomarker for PI3K 
inhibition. 1 µM GDC-0941 was sufficient to ablate pAKT 
in both cell lines across conditions (Figure 1). 
FTC-133 cells have hyperactive PI3K activity by 
virtue of PTEN loss, a commonly observed event in thyroid 
and other cancers. We used cell variants with reconstituted 
PTEN to enable comparison of pharmacological and 
genetic inhibition of the PI3K pathway: Western blotting 
of pPIKK in the paired cells did not phenocopy GDC-
0941-mediated effects on pATR. However, as observed 
with GDC-0941 treatment, radiation-induced pATM 
and pDNA-PKcs activation was compromised in PTEN 
reconstituted cells, following irradiation of anoxic cells 
suggesting dependency on PI3K (Figure 2). 
Pharmacological and genetic inhibition of PI3K 
prolongs radiation-induced DNA damage and 
reduces clonogenic survival in anoxic FTC and 
ATC cells
To determine if the observed effects of PI3K on PIKK 
activation influenced cellular response to radiotherapy, we 
evaluated DNA damage through induction and persistence 
of γH2AX expression following irradiation in normoxia and 
anoxia. In both conditions, GDC-0941 increased and prolonged 
γH2AX expression (Figure 3). Experiments were repeated 
using immortalised normal thyroid cells and here GDC-0941 
had no effect on γH2AX expression over that observed with 
radiation alone (Figure 4). The persistence of DNA damage at 
prolonged times post-radiotherapy is commonly an indicator 
of the extent of potentially lethal DNA damage repair. To 
ascertain whether these changes correlated with survival, cells 
remained exposed to drug for 20 h following irradiation and 
were then seeded for clonogenic survival assays. Surprisingly, 
for both FTC-133 and 8505c cells irradiated under normoxia, 
the observed persistence of elevated γH2AX expression in 
GDC-0941 treated cells did not translate to reduced clonogenic 
survival (Figure 5). As anticipated, under anoxia, vehicle-
treated cells displayed radioresistance compared with cells 
exposed to radiation in normoxia conditions. GDC-0941 
treatment caused sensitization to anoxic-radiotherapy in both 
cell lines, with much more pronounced enhancement in FTC-
133 cells (Figure 5). The effects of GDC-0941 on the extent 
and prolongation of γH2AX expression were phenocopied by 
PTEN reconstitution in FTC-133 cells. Again no significant 
effects of PI3K inhibition via PTEN were observed in terms of 
clonogenic survival following radiation treatment in normoxia 
(Figure 6). Significant sensitization was observed under 
anoxia, but interestingly, the magnitude was much reduced 
compared to GDC-0941 treated wildtype cells and mirrored 
more that observed in the 8505c model. 
GDC-0941 abrogates radiation-mediated effects 
on cell cycle 
FTC-133 and 8505c cells were treated as for the 
clonogenic assay but instead of seeding for clonogenicity, 
cells were fixed and cell cycle distribution analysed by flow 
cytometry. GDC-0941 induced pronounced G1 phase arrest 
in both cell lines in both normoxic and anoxic conditions 
(Figure 7). The effect was markedly greater than the increased 
proportion of cells observed in the G1 phase following 
exposure to anoxia alone. Radiation had differential effects 
in FTC-133 and 8505c cells, inducing G1 and G2 arrest 
respectively after irradiation in normoxic and anoxic conditions 
(Figure 7). Combination of GDC-0941 clearly abrogated the 
cell cycle arrest observed in FTC-133 cells in both normoxia 
and anoxia. Similarly, the pronounced cell cycle changes 
observed in 8505c cells treated with either radiation or GDC-
0941 alone were abrogated in co-treated cells. As detailed 
above, in both models, GDC-0941 inhibits activation of ATR 
following radiation treatment irrespective of oxygen condition. 
In previous studies direct targeting of ATR results in abrogation 
of cell cycle checkpoints following radiation treatment [18], 
consistent with the changes observed here, which may be 
associated with the marked inhibition of ATR activity.
Effects of GDC-0941 on PIKK protein activation 
is maintained in irradiated human FTC-133 
xenografts 
We have previously reported that GDC-0941 
treatment significantly reduces the growth of FTC-133 
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Figure 1: Under anoxia, radiation-induced PIKK activation is markedly inhibited by GDC-0941. PIKK activation was 
assessed via analysis of phospho(p)PIKK protein expression. In FTC-133 and 8505c cells, GDC-0941 inhibited expression of pATR 
at concentrations ≤ 1 µM under both normoxia and anoxia. Under normoxia, GDC-0941 inhibited pDNA-PKcs expression at higher 
concentrations; ≤ 10 µM in FTC-133’s and 100 µM 8505c’s. Under anoxia, pDNA-PKcs was much more sensitive to GDC-0941, with 
almost complete inhibition observed at 1 µM GDC-0941 in both cell lines. Under normoxia, GDC-0941 had little effect on pATM, whilst 
a clear inhibition was observed in both cell lines under anoxia. Cells were exposed to GDC-0941 in normoxia/anoxia for 18 h, irradiated 
(4 Gy) whilst remaining in the specified conditions and lysates collected 1 h later for analysis. Cropped blots are representative of 4 
independent experiments. 
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tumours and has pronounced anti-metastatic effects [14, 
19]. To determine if the GDC-0941 mediated effects on 
PIKK activation translated in vivo, we first ascertained 
total PIKK expression by IHC in mice bearing human FTC 
xenografts. Interestingly, we found that out of 16 FTC 
xenografts analysed 4.5% and 18.2% of FTCs displayed 
complete loss of ATM and DNA-PKcs respectively, (data 
not depicted). FTC-133 tumours were treated with 2 Gy 
fractions of radiation over 5 consecutive days and dosed 
with 50 mg/kg GDC-0941 or vehicle twice daily, 4 h prior 
and immediately post radiation. Tumours were excised and 
snap frozen 1 h after the final dose and assessed for pPIKK 
expression. GDC-0941 significantly inhibited PI3K 
activity ascertained by pAKT expression in irradiated 
xenografts. Similar to in vitro observations GDC-0941 
significantly inhibited pATM and pDNA-PKcs expression, 
and reduced expression of pATR, which coincided with a 
significant increase in γH2AX expression compared with 
tumours treated with radiation alone (Figure 8).
GDC-0941 significantly improves the outcome of 
radiotherapy in human FTC-133 xenografts
To explore the effect of combining GDC-0941 
with radiotherapy on tumour growth, mice bearing FTC-
133 xenografts were treated with 2 Gy fractions over 5 
consecutive days combined with 50 mg/kg GDC-0941 or 
vehicle (twice daily) for 14 days. GDC-0941 significantly 
improved radiotherapy outcome compared to vehicle 
treated controls, with one tumour showing complete 
regression (Figure 9A). GDC-0941 increased post-
radiation tumour regression, and significantly increased 
the time taken for tumours to triple in size (RTV3: 
26.5 ± 5 days for radiation alone versus 31.5 ± 5 days 
for the dual treatment; p < 0.05). Importantly, GDC-0941 
did not affect pAKT expression in irradiated skin that was 
covering the tumour (Figure 9B), suggesting that at the 
dose given, GDC-0941 selectively radiosensitises tumour 
cells, and does not radiosensitise normal tissue. 
Figure 2: Under anoxia, genetic inhibition of PI3K inhibits radiation-induced ATM and DNA-PKcs activation. PIKK 
activation was assessed via analysis of phospho(p)PIKK protein expression. Genetic inhibition of PI3K (via PTEN reconstitution into 
PTEN-null FTC-133 cells) had little effect on pATR expression under normoxia and anoxia. Radiation-induced pATM and pDNA-PKcs 
were inhibited in anoxic PTEN-expressing cells. PCI NEO and PTEN reconstituted FTC-133 cells were incubated in normoxia/anoxia 
for 18 h irradiated (4 Gy) whilst remaining in the specified conditions and lysates collected 1 h later for analysis. Cropped blots are 
representative of 4 independent experiments. 
Oncotarget63111www.impactjournals.com/oncotarget
Elegant studies have revealed that an alternate 
mechanism by which PI3K targeting strategies can 
enhance tumour response to radiotherapy is by reducing 
oxygen consumption within cells, consequently leading to 
a reduced hypoxic fraction within treated tumours [20]. 
As the level of hypoxia in tumours associates with the 
extent of radiotherapy resistance, we analysed hypoxia 
in tumours at treatment size and after the 5th 2 Gy 
dose of radiation, with and without co-incidental GDC-
0941. To enable this assessment, mice were treated with 
pimonidazole, a hypoxic marker, prior to tumour excision. 
Tumour hypoxia was assessed via IHC for pimonidazole 
adducts. Irradiated tumours had a significantly higher 
hypoxic fraction versus unirradiated controls. No 
significant differences in hypoxic fraction were observed 
in GDC-0941 versus vehicle treated irradiated tumours 
(Figure 9C). This was not due to tumour size as this did 
significantly differ between the two groups at the excision 
time point (456 ± 132 mm3 (vehicle-treated) versus 342 ± 
82 mm3 (GDC-0941-treated)). 
Figure 3: Pharmacological inhibition of PI3K increases and prolongs radiation-induced DNA damage across oxygen 
environments. (A–B) GDC-0941 increases γH2AX expression 1 and 24 h post irradiation under normoxia and anoxia (*p < 0.05, 
**p < 0.01 compared to vehicle (DMSO) in same condition). Examples of immuno-fluorescence images of γH2AX under anoxia are 
shown. FTC-133 and 8505c cells were incubated under normoxia/anoxia for 18 h with DMSO or 10 μM GDC-0941 and irradiated (4 Gy) 
in the specified conditions. Samples remained in the specified conditions until fixation 1 and 24 h post 4 Gy. DNA damage was assessed 
by expression of γH2AX that was displayed as fold change of 0 Gy DMSO for each condition. Nuclei were counterstained with DAPI. 
 Scale-bar 10 µm. Data represents the mean ± S.D. of 3 independent experiments. 
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PIKK proteins are a viable target in human 
thyroid cancers
To ascertain the expression of PIKK proteins within 
and between classifications of human thyroid tumours, 
IHC was performed on 12 tumours representative of PTC 
and ATC and 13 FTCs. Intensity and distribution of the 
PIKK proteins differed from very weak to very intense 
nuclear staining. Distribution also varied from very diffuse 
to more focal isolated regions of staining (Figure 10A). 
Interestingly other cell types within the tumours varied for 
PIKK staining: stromal cells appeared to be negative for 
PIKK proteins, whereas tumour lymphocytes expressed all 
PIKK proteins but staining varied from weak to intense. 
Skeletal muscle that had been infiltrated by tumour cells 
was mainly negative for ATM/ATR but some staining 
was seen for DNA-PKcs (data not shown). Both ATR and 
DNA-PKcs expression was higher than ATM in all tumour 
classifications (Figure 10B). All ATCs examined expressed 
all of the PIKK proteins. ATM was expressed in 91.7% 
and 85.7% of PTCs and FTCs, and DNA-PKcs in 85.7% 
of FTCs analysed. Normal thyroid tissue was positive for 
the PIKK panel, with expression limited to the epithelium 
cells of the follicles lining the colloid space. Human tonsil 
was used as a known positive control for the PIKKs and 
concentration-matched isotype IgG antibodies were used 
on tonsil tissue for negative controls (Figure 10C).
DISCUSSION
Currently, no conventional combined chemo/
radiotherapies exist that significantly prolong life in 
patients with aggressive, radioresistant FTCs and ATCs 
[3]. Furthermore, the underlying molecular mechanisms 
contributing to these phenotypes are complex and remain 
poorly understood. A key pathway that contributes to 
thyroid cancer progression and radioresistance is the PI3K 
pathway [1, 7]. Here we explored the inter-relationship 
between PI3K and the PIKK proteins in irradiated thyroid 
cancer cells and determined if this differed depending 
on the oxygen environment. This is important since 
most solid tumours including thyroid contain regions 
of hypoxia; a condition fundamentally associated with 
radioresistance. 
The PIKK proteins share significant sequence 
homology with PI3K [21, 22] therefore drugs targeting 
PI3K may also inhibit PIKK activity. Here we propose 
that inhibition of radiation-induced ATR is a GDC-0941 
associated effect and not affected by oxygen tension. This 
is because whilst ATR activation was markedly inhibited 
by GDC-0941 in both cell lines, no effect on ATR 
activation was seen on PTEN reconstitution in FTC cells. 
In contrast, we propose that radiation-induced 
ATM and DNA-PKcs activation has dependency on PI3K 
under anoxia; shown by inhibition of pATM and DNA-
PKcs in both GDC-0941 treated and PTEN reconstituted 
cells, when compared to effects in normoxia. Further, 
this effect was more pronounced in FTC cells compared 
to that observed in 8505c cells: FTC133 cells harbour 
loss of PTEN, whereas 8505c cells predominantly carry 
a BRAFV600 mutation with some co-reliance on PI3K 
(described in [19, 23]). As effects on radiation-induced 
ATM and DNA-PKcs activation were more marked in the 
FTC line, this links a thyroid model that is predominantly 
driven by PI3K to a regulatory effect on ATM and DNA-
PKcs activation. 
It is known that at concentrations used in the 
functional studies (10 µM) GDC-0941 directly inhibits 
DNA-PKcs [17], and in accord with this we observed a 
dose-dependent reduction in DNA-PKcs activity in both 
Figure 4: GDC-0941 does not affect radiation-induced DNA damage in immortalised thyroid cells. Radiotherapy increased 
γH2AX expression to similar levels to that observed in thyroid carcinoma cell lines but had little effect under anoxia. GDC-0941 had little 
effect on radiation-induced DNA damage under normoxia or anoxia. Immortalised thyroid cells were treated and analysed as described in 
figure legend 3. Data represents the mean ± S.D. of 3 experimental repeats. 
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cell lines. However, we observed inhibition of DNA-PKcs 
activity on PTEN reconstitution suggesting that although 
GDC-0941 may directly inhibit DNA-PKcs in these 
studies, there is also a dependency on PI3K for radiation-
induced activation. 
From our observations, the combined inhibitory 
effect of anoxia and GDC-0941 on PIKK activation was 
much greater than GDC-0941 alone. This may provide a 
mechanism for why GDC-0941 only reduced clonogenic 
survival in anoxic cells. Whilst reduced clonogenic 
survival was also observed in anoxic PTEN-expressing 
FTC133 cells; the magnitude of radiosensitisation 
was much less than with GDC-0941. This may reflect 
differences in GDC-0941 associated effects (inhibits all 
PIKKs) versus PI3K associated effects on ATM and DNA-
PKcs activity only.
GDC-0941 abrogated radiation-induced cell 
cycle arrest. It has been shown that direct inhibition of 
ATR leads to abrogation of cell cycle checkpoints via 
modulation of Chk1 [18, 24]. Therefore, the marked 
inhibitory effect by GDC-0941 on ATR may contribute to 
the abrogation of radiation-mediated cell cycle arrest in all 
conditions. Since PI3K-inhibition only reduced clonogenic 
survival under anoxia, we postulate that PI3K-inhibition 
combined with radiation may lead to a cytostatic outcome 
under normoxia, but a cytotoxic effect under anoxia. In 
anoxia, the G2 arrest is less pronounced, and activity of 
all PIKKs is inhibited; ATM also contributes significantly 
Figure 5: GDC-0941 reduces clonogenic survival of anoxic cells. GDC-0941 had little effect on clonogenic survival under 
normoxia but significantly inhibited survival under anoxia (*p < 0.05 versus DMSO). For clonogenic assays, cells were incubated under 
normoxia/anoxia for 18 h with DMSO or 10 µM GDC-0941and irradiated (4 Gy) in the specified conditions. Samples remained in the 
specified conditions for 24 h post irradiation, then plated in serial dilution and cultured until visible colonies formed. Data represents the 
mean ± S.D. of 3 independent experiments.
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to cell cycle control [24, 25]. Therefore the combination 
of these effects may account for the radiosensitisation 
observed under anoxia.
Collectively, these data suggest that GDC-0941 
works by ablating a number of key cellular responses to 
radiation damage: DNA repair (via inhibition of ATM, 
ATR and DNA-PKcs activity), cell cycle (via inhibition 
of ATR and ATM) and cell survival (via PI3K inhibition). 
To determine if this translated into a more realistic 
setting, mice bearing human FTC xenografts were treated 
with radiotherapy/GDC-0941 and effects on pPIKK 
expression and tumour growth explored. Importantly 
the GDC-0941 mediated inhibitory effects on radiation-
induced PIKK activation translated in vivo in FTC133 
xenografts leading to a significant radiosensitisation: 
Tumour growth delay was increased post radiotherapy 
in GDC-0941-treated mice. Since hypoxia promotes 
radioresistance it is important to highlight that cotreatment 
with GDC-0941 firstly did not radiosensitise normal 
thyroid cells or exposed skin, which likely reflects 
differences in PI3K hyperactivity and secondly, did not 
enhance radiation-induced increases in hypoxic fraction. 
Clinically these data highlight two important therapeutic 
characteristics; that GDC-0941 does not radio-sensitise 
Figure 6: Genetic inhibition of PI3K increases and prolongs radiation-induced DNA damage across oxygen environments 
but selectively inhibits clonogenic survival of anoxic cells. PTEN reconstitution in FTC-133 cells significantly increased γH2AX 
expression 1 and 24 h post irradiation under normoxia and anoxia (*p < 0.05, **p < 0.001) and reduced clonogenic survival under anoxia 
(*p < 0.05 versus DMSO), whilst having little effect under normoxia. PCI NEO and PTEN reconstituted FTC-133 cells were incubated 
under normoxia/anoxia for 18 h and irradiated (4 Gy) under condition. Cells then remained in normoxia/anoxia and were either fixed 1 and 
24 h post 4 Gy for analysis of γH2AX expression or seeded in serial dilution 24 h post 4 Gy, and cultured until visible colonies formed for 
clonogenic survival assays. DNA damage was assessed by expression of γH2AX and displayed as fold change of 0 Gy PCI NEO for each 
condition. Nuclei were counterstained with DAPI. Scale-bar 10 µm. Data represents the mean ± S.D. of 3 independent experiments. 
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Figure 7: GDC-0941 abrogates radiation-mediated effects on cell cycle. In un-irradiated cell lines, GDC-0941 and anoxia 
independently increased percentage cells in G0/G1 (*p < 0.05, **p < 0.01). Radiation had differential effects across cell lines; significantly 
increasing percentage cells in G0/G1 (FTC-133) and G2/M (8505c) under normoxia and anoxia (§p < 0.05, §§p < 0.01). In irradiated FTC-
133 cells, GDC-0941 significantly reduced percentage cells in G0/G1 under normoxia and anoxia (*p < 0.05). In irradiated 8505c cells, 
GDC-0941 significantly reduced percentage cells in G2/M under normoxia (*p < 0.05), with similar affects observed in anoxia. As for 
the clonogenic assays, FTC-133 and 8505c cells were incubated under normoxia/anoxia for 18 h with DMSO or 10 µM GDC-0941 and 
irradiated (4 Gy) in the specified conditions. Samples remained in the specified conditions for 24 h post irradiation, but instead of seeding 
for clonogenicity, samples were fixed and cell cycle distribution was assessed by flow cytometry analysis of propidium iodide stained cells. 
Data represents the mean ± S.E.M. of 3 independent experiments. 
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Figure 8: GDC-0941 inhibits PIKK activation and increases DNA damage in irradiated human FTC xenografts. 
In irradiated FTC133 xenografts, GDC-0941 reduces pATR expression and significantly reduces pATM and pDNA-PKcs expression 
(*p < 0.05), whilst γH2AX expression is significantly increased (*p < 0.05). Inhibition of PI3K was confirmed by analysis of pAKT 
expression, which was reduced in GDC-0941 versus vehicle treated tumours (**p < 0.01). Mice received vehicle or 50 mg/kg GDC-0941 
(p.o.) 4 h prior and immediately after radiotherapy (10 Gy fractionated (2 Gy) over 5 consecutive days). 1 h after the final dose, tumours 
were rapidly excised and immediately snap frozen for analysis of PIKK activity by western-blot of pPIKK expression. Cropped blot 
represents irradiated tumours from 4 independent mice that received either vehicle or GDC-0941. Graph represents densitometry data for 
the calculated mean ± S.D of the depicted western-blot.
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Figure 9: GDC-0941 increases tumour regression post-radiotherapy. Mice were dosed twice daily (p.o.) with vehicle or 50 mg/
kg GDC-0941 for 14 d. Tumours received 10 Gy radiation fractionated into 2 Gy over 5 days (treatment days 1-5). On these days vehicle/
GDC-0941 was administered 4 h prior and immediately after radiation. (A) Mice dosed with GDC-0941 had significantly smaller tumour 
volumes on days 4–12, 22,23,25 and 26 (*p < 0.05, **p < 0.01, ***p < 0.001 versus vehicle treated mice). Data displayed shows up until 
the time when vehicle treated mice reached the designated end-point of three times the relative tumour volume (RTV3: 26.5 ± 5 days for 
radiation alone versus 31.5 ± 5 days for GDC-0941/radiation; p < 0.05). Data shown is for 11 vehicle and 9 GDC-0941 treated mice, Data 
represents the mean ± S.D. §One co-treated tumour regressed completely and was excluded from analysis. (B) Mice received vehicle or 50 
mg/kg GDC-0941 (p.o.) 4 h prior and immediately after radiotherapy (10 Gy fractionated (2 Gy) over 5 consecutive days). 1 h after the 
final dose, skin exposed to radiation (that covering the tumour) was excised, snap frozen and homogenised in lysis buffer for western-blot 
analysis. GDC-0941 did not affect pAKT expression in skin tissue exposed to radiotherapy. Cropped blot shows pAKT, tAKT and the 
loading control β-actin for mice that received radiation with either vehicle (n = 4) or with GDC-0941 (n = 4). (C) Tumour hypoxia was 
measured by IHC analysis of pimonidazole, dosed at 60 mg/kg (i.p.) 2 h prior to tumour excision. A significant increase in hypoxic fraction 
was observed in irradiated vehicle and GDC-0941 treated tumours (*p < 0.05 versus un-irradiated). GDC-0941 had no significant effect on 
hypoxic-fraction compared to vehicle in irradiated xenografts. Tumour volume did not significantly differ between groups. Data represents 
the mean ± S.D. of 4-5 mice per group.
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Figure 10: The PIKKS are a viable target in human thyroid cancer. (A) Representative images of PIKK staining (brown). 
Intensity and distribution of PIKK proteins varied within each tumour classification. Representative images from three independent tumours 
are shown. Scale bar 1700 µm (for ATR and DNA-PKcs images) and 2000 µm (for ATM images). (B) PIKK expression was scored based on 
intensity and proportion of staining (described in methods). ATR and DNA-PKcs expression was significantly higher versus ATM in PTCs/
ATCs and ATR expression significantly higher versus ATM in FTCs (*p < 0.05, **p < 0.01). Data represents mean ± S.E.M. of 12 PTC/
ATC and 13 FTC. (C) Thyroid tissue stained positive for ATM, ATR and DNA-PKcs. Human tonsil was used as a known positive control 
for PIKK expression. Additionally tonsil tissue was exposed to the appropriate concentration matched IgG isotype antibodies as a negative 
control. See methods for full details. Scale bar 119 µm.
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non-cancerous tissue but selectively targets cancerous 
cells, and does not increase the radioresistant hypoxic 
fraction. 
We show that the PIKK proteins are viable 
therapeutic targets in human thyroid cancers, as PIKKs 
were highly expressed across classifications, with ATM 
scoring consistently lower. Expression did not significantly 
differ between classifications but interestingly, some 
loss of PIKK proteins was observed in PTCs and FTCs. 
Loss of certain PIKKs may additionally open up new 
therapeutic strategies by virtue of a synthetic lethality 
approach. For example, we found that ATM was lost in 
8.3% of PTCs and 14.3% of FTCs. Since one of the major 
DNA repair mechanisms, homologous recombination, 
is compromised due to loss of ATM in these tumour 
subsets; this may drive reliance of these cancer cells on 
the remaining DDR pathways to survive inflicted DNA 
damage. Therefore inhibiting other key components of the 
DRR response such as ATR and DNA-PKcs may sensitise 
thyroid cancer cells to DNA damaging therapy. In accord 
with this, similar synthetic lethality approaches have been 
successful in a range of tumour types [26]. 
Interestingly other cell types within the tumours 
varied for PIKK staining. Thus, there was significant 
heterogeneity of PIKK expression within the different 
tumour–associated cell populations. These findings 
suggest that activation of PIKK proteins in other cells 
within the tumour microenvironment may also contribute 
to the DNA damage response and tumour cell survival 
post radiotherapy. Unfortunately, we were unable to detect 
pPIKK expression owing to technical problems with 
phospho-antibody staining. 
In summary, inhibition of radiation-induced 
ATR activity is a GDC-0941 associated effect, whereas 
radiation-induced ATM and DNA-PKcs activation has 
dependency on PI3K, is associated more with hypoxia 
and is more pronounced in FTCs with a PTEN mutation: 
This links a thyroid model that is predominantly driven 
by PI3K, to a regulatory role on ATM and DNA-PKcs. 
From our observations both the ATM and DNA-PKcs only 
effect (reduced activation in irradiated PTEN mutant cells 
under anoxia) or the ATR only effect (reduced activation 
in irradiated 8505c cells treated with GDC-0941 under 
anoxia) causes some hypoxic radiosensitisation. However 
this is more pronounced if both the PI3K pathway and 
PIKK activation is abrogated, as seen with GDC-0941 in 
irradiated FTC cells, under anoxia. 
Importantly, we show that these interactions 
between the PI3K pathway and PIKK activity exist in 
human xenografts and contribute to radioresistance. 
We further show that the PIKKs are viable therapeutic 
targets in human tumour samples. These data provide new 
insight into the mechanisms of radioresistance in thyroid 
carcinoma that has important therapeutic implications. 
MATERIALS AND METHODS
Cell culture 
FTC (FTC-133), ATC (8505c), and derivative cell 
lines are described previously [19]. FTC-133 cells stably 
expressing PTEN and PCI-NEO [27], kindly provided by 
Professor Oliver Gimm, University of Linkoping, Sweden) 
were cultured in media containing 1 mg/ml G418. 
Immortalized thyroid cells [28] were cultured in standard 
RMPI medium supplemented with 10% fetal calf serum 
and 2 mM L-glutamine. Low passage 8505c cells were 
used in all studies, purchased from DSMZ, Braunschweig, 
Germany. FTC-133 parental and variant cell lines were 
authenticated post studies by short tandem repeat (STR) 
profiling. The percentage match given against the STR 
profile from the European Collection of Authenticated Cell 
Cultures (ECACC) was 91.3%.
Exposure to anoxia
Cells were gassed with 5% CO2:5% H2:90% N2 
through a palladium catalyst in an anaerobic chamber 
(Sheldon Manufacturing, Cornelius, OR). 
Radiation treatments
Cells were irradiated (Faxitron X-ray; Faxitron 
Bioptics, Lincolnshire, USA) in sealed airtight containers 
under the appropriate O2-tension. X-ray doses were given 
at a rate of 0.952 Gy/min. Cells were then transferred back 
to the appropriate experimental condition for a specified 
time period depending on the study.
Immuno-fluorescence and γH2AX quantification
Cells were fixed and permeablised 1 and 24 h post 
irradiation. GDC-0941 treated cells were maintained in drug 
for the times indicated post irradiation. Fixed cells were 
incubated with a primary antibody against γH2AX for 1h 
at 37°C, washed and incubated with a secondary antibody 
(AlexaFluor598: Life technologies Ltd, Paisley, UK) for 
45 min at 37°C. Nuclei were counter-stained with 4ʹ,6-
diamidino-2-phenylindole (DAPI). γH2AX expression was 
visualised at 200X magnification on a Snapshot Widefield 
(Olympus BX51) upright fluorescence microscope 
using a 10×/0.30 Plan Fln objective and captured using 
a Coolsnap ES camera (Photometrics) and MetaVue 
Software (Molecular Devices). Pictures of three fields of 
view were taken totalling 100 cells per experiment. Average 
γH2AX expression was quantified by calculating average 
fluorescence intensity of γH2AX per nucleus. Expression 
was displayed as fold change of the untreated 0 Gy control 
in the relevant condition unless stated otherwise.
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Western-blotting
Protocols were used as previously described [29]. 
For PIKK analysis 70 µg protein was loaded per well on 
density gradient SDS-PAGE gels to allow detection of the 
lower molecular weight loading control protein β-actin on 
the same gel. 
Primary antibodies
Antibodies used were mouse monoclonals; γH2AX 
(Millipore (U.K.) Ltd, Watford, UK), Pimonidazole 
(Hydroxyprobe 1 clone 4.3.11.3, Natural Pharmacia 
International Inc, Burlington, USA), AKT-phospho (p) 
S473 (Cell Signaling Technology, CA, USA), and β-actin 
(Sigma-Aldrich, Gillingham, UK). Rabbit monoclonals 
used were: ATM-pS981, total (t)-ATM, DNA-PK-pS2056, 
tDNA-PK, Isotype control rabbit IgG (Epitomics, CA, 
USA). Rabbit polyclonals used were; ATR-pS428, tATR, 
tAKT (Cell Signaling Technology, CA, USA) and rabbit 
IgG (Vector Laboratories Ltd, Peterborough, UK).
Clonogenic survival assays
Cell cultures were incubated in normoxia/anoxia for 
4 h, irradiated and put back in condition (for stable clones) 
or immediately treated with 10 μM GDC-0941 or vehicle 
(DMSO)in condition, and left for a further 20 h. Cells 
were then plated at low seeding densities and cultured for 
10 to 12 d. Colonies were stained with methylene blue 
and counted. Colony-forming efficiency was normalised 
to that of the appropriate control.
Cell cycle analysis
Cells were treated as in the clonogenic assay. At the 
point of seeding for colony formation, cells were stained 
with propidium iodide solution, for cell cycle analysis as 
described [30]. 
Xenograft studies
To initiate xenografts, FTC-133 cells were implanted 
sub-cutaneously (0.1 ml of a 5 × 107/ml stock in PBS) in 
female nude mice (CBA nu/nu, aged 8–12 weeks, weight 
range; 20–27 g) and tumour volume measured at least 
five times weekly and weight daily. Mice were randomly 
assigned into treatment groups and radiotherapies 
commenced when FTC-133 tumours reached 200–250 mm3. 
GDC-0941 was prepared in 0.5% hydroxypropyl 
methylcellulose (vehicle) and administered by oral gavage 
(p.o.). GDC-0941 was dosed in 0.1 ml/10g body weight. 
Mice were dosed twice daily with vehicle or 50 mg/kg 
GDC-0941 combined with radiation (10Gy fractionated into 
2 Gy over 5 consecutive days (d)). On radiation days, mice 
received the first dose 4 h prior to radiation and the second 
dose immediately after. For analysis of GDC-0941-mediated 
effects on the primary tumour, tumours were rapidly excised 
1 h after the final dose of vehicle/drug and immediately snap 
frozen. For analysis of radiosensitization, dosing regimes 
continued for 9 d post radiotherapy. Tumours were excised 
at maximum burden (900–1000 mm3). 
All procedures were carried out in accordance with 
the Animals in Scientific Procedures Act 1986 and in line 
with the guidelines for the welfare and use of animals in 
cancer 2010 [31]. Protocols were ethically approved by 
the University of Manchester Animal Welfare and Ethical 
Review Body and were conducted with the highest 
standard of welfare under the authority of Home Office 
project license 40/3112 (held by Professor K.J.W.). 
Patient samples 
For the use of thyroid carcinoma tissue, patient 
informed consent and ethical approval was obtained from 
the Faculty of Medicine ethics commission board at the 
Martin Luther University of Halle-Wittenberg, Germany, 
as previously described [29]. The human tonsil tissue 
was sourced as an anonymous control from the Histology 
archive at the Cancer Research UK Manchester Institute, 
Manchester, UK.
Immunohistochemistry (IHC)
12 PTC, 13 FTC and 12 ATC samples were 
histologically evaluated and used for analysis of total 
PIKK expression. Samples were dewaxed, rehydrated 
and antigen retrieval performed in a pascal pressure 
retriever (DAKO UK Ltd, Ely, UK) that heated samples 
to 125°C for 1 min, then 90°C for 10 min. Target retrieval 
solution pH9 and pH6 was used for ATM/DNA-PK and 
ATR respectively. Samples were incubated in hydrogen 
peroxide block solution (10 min at room temperature 
(RT)), washed and blocked with protein blocking 
solution (DAKO: 5 min at RT). ATM, ATR, DNA-PK 
and pimonidazole (Hydroxyprobe 1 clone 4.3.11.3) 
antibodies were diluted 1:200, 1:50, 1:25 and 1:50 
respectively. Appropriate isotype control IgG antibodies 
were concentration matched to the primary antibody and 
used as negative controls. Human tonsil was used as a 
positive–staining control. Samples were incubated for 1 h 
at RT with primary antibody, washed and incubated with 
Envision system HRP labelled rabbit or mouse polymer 
(DAKO: 30 min at RT) and stained with diaminobenzidene 
solution (DAKO:10 min). Slides were counterstained with 
Mayer’s haemotoxylin, dehydrated and mounted. Images 
were captured using a Leica SCN400 imaging analyzer 
(Leica Microsystems (UK) Ltd, Milton Keynes, UK). 
Samples were scored according to protocols adapted from 
[32] as described previously [29] . PIKK protein staining 
and expression was validated and scored by a consultant 
histopathologist. This scoring allowed for necrosis, tumour 
heterogeneity and lymphoid infiltration. 
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Statistical analysis
One-way ANOVA with Tukey post hoc test and 
Student’s t tests were used.
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